Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in ”lagen (1991:980) om handel med finansiella instrument” it’s hereby announced that through the  subscription by a new share issue related to the company’s stock option program in Aerocrine the number of shares and votes in Aerocrine has increased during January 2015 as specified in the table below. (PLEASE NOTE THAT THE CHANGE IN NUMBER OF SHARES DUE TO THE ONGOING RIGHTS SHARE ISSUE WILL BE PUBLISHED ON FEBRUARY 27TH).

Number of shares and votes
January 1, 2015 155 063 162
Increase 353 225
January 30, 2015 155 416 387

Solna January 30, 2015

Aerocrine AB (publ.)

For further information, please contact:

Marshall Woodworth, CFO, +1 919 749 8748 or +46 709 695 219

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX VERO®, which enables fast and reliable point-of-care measurement of airway inflammation. These products plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com .

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on January 30, 2015.

About Us

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Subscribe

Documents & Links